The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.

First-in-human study starts include radioligands from Akiram and Philogen.

A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.

The French group takes a shot at Perspective with its second bet on Orano Med.

Jazz's somewhat low-key SCLC drug scores its biggest win yet.

The Hutchmed-originated savolitinib moves towards its first US approval.

Meanwhile, Tecvayli stalls, but J&J still hopes for growth.

OncoC4’s AI-081 features among the industry’s latest first-in-human trial initiations.

The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.

The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.